Oxurion NV and Prevent Blindness are teaming up for November’s Diabetes-related Eye Disease Awareness Month.

“The number of diabetes cases continues to soar,” said Jeff Todd, president and CEO of Prevent Blindness. “Through awareness and education, our goal is to minimize the damaging effects that diabetes can have on vision.”

CHICAGO (PRWEB)
October 30, 2019

Today, more than 30 million Americans have diabetes (about 1 in 10), and 90-95 percent of them have type 2 diabetes, according to the Centers for Disease Control and Prevention. All those with diabetes are at risk of developing certain eye diseases, including diabetes-related retinopathy, diabetes-related macular edema, cataract and glaucoma. Diabetes is the leading cause of new cases of blindness in adults.

For the second consecutive year, Oxurion NV, a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, has partnered with Prevent Blindness, the nation’s oldest voluntary eye health and safety organization, during November’s Diabetes-related Eye Disease Awareness Month. Both groups will work to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.

“The number of diabetes cases continues to soar,” said Jeff Todd, president and CEO of Prevent Blindness. “Through awareness and education, our goal is to minimize the damaging effects that diabetes can have on vision.”

“Many people may not be aware of the impact that diabetes can have on vision, which can affect everything from quality of life, to the ability to remain independent,” said Patrik De Haes, M.D., CEO of Oxurion NV. “By working with Prevent Blindness once again, we are able to offer hope and help to the millions of patients with diabetes, and their caregivers, through our various resources.”

For more information on diabetes-related eye disease, please call Prevent Blindness at (800) 331-2020 or visit preventblindness.org/diabetes. For those who have or who care for someone with Low Vision from diabetes, visit the Prevent Blindness free online resource, Living Well with Low Vision: http://lowvision.preventblindness.org.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call (800) 331-2020. Or, visit us on the Web at preventblindness.org or facebook.com/preventblindness.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Oxurion’s clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME) and MacTel1; THR-149, a plasma kallikrein inhibitor for the treatment of DME; and THR- 687, a pan-RGD integrin antagonist for the treatment of diabetic retinopathy and DME. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.

Oxurion owns the global rights to Jetrea® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics, Inc. as a subsidiary company. More information is available at http://www.oxurion.com.

Share article on social media or email:

Cardone Ventures

“We’ll be able to tackle the opioid epidemic”

CAMAS, Wash. (PRWEB)
October 30, 2019

In order to advance the influence of integrated medicine into the healthcare space, Advanced Medical Integration (AMI) and Cardone Ventures (CV) entered into a formal business relationship that leverages the combined network of Advanced Medical Integration, Doctors Vendors Network (DVN), and Azon, LLC with Cardone Ventures (a Cardone Capital company).

Advanced Medical Integration, http://www.amidoctors.com, a Clearwater, Florida based corporation, founded by Michael Carberry, DC and Coleen Carberry, PT, is the nation’s leading consulting group for establishing holistic, philosophically-based medical integration, whether new or existing to medical integration. AMI provides systems and processes to help develop practices to a new standard in holistic medical services. They provide practitioners a proven path to make positive changes by having a principled, multi-disciplinary team under one roof, providing the best possible care for patients. AMI believes that societal healthcare trends, and the lack of responsible, holistic practitioners, have led to the current opioid epidemic in the United States.

“Due to the challenges facing health care, practices, and health care business, we need strategic partnerships aligned with helping us leverage our network of chiropractors, MDs and other licensed providers to show them how to not only survive, but to thrive in practice,” said Carberry. “We feel that partnering with Cardone Ventures through the alignment of their vast knowledge, expertise and services, we’ll be able to tackle the opioid epidemic and help empower our network to help patients take back their choices in healthcare.”

Cardone Ventures, a Vancouver, Washington, based corporation was founded by Grant Cardone, Co-Founder and Chairman, and Brandon Dawson, Co-Founder, CEO and Managing Partner, in order to guide, advise and provide the tools to transform and scale independently-owned businesses. The company has developed a focused approach designed to evaluate business maturity by enabling a business owner to diagnose, design/redesign, and transform their organization to achieve and sustain performance excellence through transformational growth from a systems perspective. Cardone Ventures delivers business advisory services in the areas of strategic management that include expansion planning and operations, sales and marketing execution, financial modeling and reporting, and people development and alignment.

“It’s always been a dream of mine to work with an elite group of healthcare providers such as Advanced Medical Integration,” says Cardone. “Their dedication to providing disruptive and proven solutions to the current opioid epidemic is a mission we’re fully aligned with and we plan on working side-by-side with them as they go into battle.”

“It’s our goal to align with independent practitioners striving to make a difference for their patients through holistic patient care,” says Dawson. “At Cardone Ventures, we want to innovate alongside the team at AMI in order to elevate their network and dominate the market, while helping business owners and their staff achieve their personal, professional, and financial goals through the business.”

Businesses can work directly with Cardone Ventures to develop their personalized strategic business strategy. The strategic business strategy establishes a baseline assessment of the business gaps and then develops a plan for the business’s success. If a business owner would like to experience their business from a ​360⁰ perspective while working directly with Grant Cardone and Brandon Dawson, there’s an upcoming opportunity December 7-8, 2019 at the 10X360 event in Miami, Florida. More information can be found at http://www.cardoneventures.com/10X360

About Grant Cardone: Grant Cardone is a NY Times Best Selling Author, Entrepreneur and Private Equity Manager with $1.4 Billion in Assets Under Management. In addition to this, he is known as the #1 Sales Expert in the world today and was called by Forbes Magazine one of the top CEOs to follow on Social Media. He currently owns and operates 7 companies that do $150m in annual sales and he recently launched the Grant Cardone Foundation, whose mission is to impact the lives of children who grow up without fathers.

About Brandon Dawson: Brandon Dawson is a self-made serial entrepreneur achieving and owner/partner in $100 million in commercial real estate, two time Ernst & Young Entrepreneur-of-the-Year semifinalist, four-time INC 500 & 5000 Fastest Growing Company Award recipient, INC National Hire Power Award recipient, and five-time Portland Oregon Top Workplaces Award Recipient and Corporate Philanthropy Award recipient. He is a business leader with a passion for helping business owners amplify their vision and impact, through belief, strategy, and team alignment.

About Advanced Medical Integration: Advanced Medical Integration (AMI) is the nation’s leading consulting group for establishing a holistic, philosophically-based, medically integrated practice. Whether you are new to medical integration or already have an integrated center, AMI will help you develop your practice to the new standard in desired holistic medical services.

For more information call 310.777.0255 or email info@cardoneventures.com.

Share article on social media or email:

WCG_CenterWatch_Logo.png

FALLS CHURCH, Va. (PRWEB)
October 31, 2019

The National Patient-Centered Clinical Research Network (PCORnet)

A CenterWatch FREE Webinar

Thursday, Nov. 14, 2019, 11:00 a.m. – 12:30 p.m. EST

http://cwinfo.centerwatch.com/cw-web19n14-national-patient-centered?free_webinar_source=CWEvnt

Searching for better clinical research? Would it help if one could harness the power of large amounts of health data and patient partnerships?

PCORnet, the National Patient-Centered Clinical Research Network, is an innovative network of networks advancing the use of electronic health data in comparative effectiveness research.

Maryan Zirkle, Elizabeth Shenkman and Adrian Hernandez, at PCORnet, will show attendees how to transform the culture of clinical research from one directed by researchers to one driven by the needs of the patients and those who care for them.

During this free webinar discover effective ways to conduct clinical trials:

• 
  Transform trials with information on the patient-centered ecosystem, the distributed architecture of the network, and access to data as well as disparate data sources
• Obtain information on the health systems, health plans, and other stakeholders (communities and patients) involved in the infrastructure
• Use PCORnet as a resource in conducting various types of research such as, large pragmatic clinical trials, prospective and retrospective observational studies
• Gain advanced capabilities to recruit and enroll
• Enhance ascertainment of outcomes through the increased ability to link to partners with claims data and patient reported outcomes
• Optimize infrastructure with respect to specific conditions and communities

Conduct more efficient, patient-centered research that improves healthcare outcomes.

Webinar Details:

The National Patient-Centered Clinical Research Network (PCORnet)

A CenterWatch FREE Webinar

Thursday, Nov. 14, 2019, 11:00 a.m. – 12:30 p.m. EST

http://cwinfo.centerwatch.com/cw-web19n14-national-patient-centered?free_webinar_source=CWEvnt

Easy Ways to Register:

Online: http://cwinfo.centerwatch.com/cw-web19n14-national-patient-centered?free_webinar_source=CWEvnt

By phone: 617-948-5100 or 866-219-3440

About CenterWatch:

Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

Share article on social media or email:

Michael DeLeon, Founder and CEO of Steered Straight, is on a mission to help kids avoid vaping and other drugs.

“We are in the worst public social health crisis America has ever seen. With vaping/JUULing and a culture that literally grew up with pills marketed as the solution for every human ailment, the threat to our youth is greater than ever.”

MURFREESBORO, Tenn. (PRWEB)
October 30, 2019

Vaping has become a cross-country epidemic, with over 1,500 reported counts of vape-related illnesses and 34 vape-induced deaths [1]. The cruel tragedy of this epidemic is that most of the victims of vaping related illnesses involve young adults around age 23 and most of the vaping related deaths are adults around age 45–but most of the long-term illnesses and death will manifest in children under 18 years old. In a recent federal survey, researchers found that more than 25 percent of U.S. high school students have used an e-cigarette in the past 30 days [2]. Michael DeLeon, the number one booked school speaker on drug related issues and Founder/President of Steered Straight, has surveyed more than 15,000 middle and high school students already this school year and has found that number is more than double.

When companies like Juul began marketing to pre-adolescents and teens with misleading messages pertaining to the safety of vaping, dependency and ingredients, their revenue spiked and sent the CDC, parents and teachers into a panic. “These companies are marketing these products to children and it’s absolutely unacceptable. We need to speak up and put an end to this dangerous fad,” said DeLeon.

Unfortunately, the anti-tobacco and anti-smoking awareness efforts are far less abundant than e-cigs and tobacco campaigns. In an effort to stop the vaping giant Juul from marketing to children, the Center for Environmental Health recently released a legally binding agreement preventing Juul from:

• 
  Advertising at sporting events or concerts that allow people under the age 21.
• Appearing at schools.
• Using models in their ads that are under the age of 28 [3].

Although these are promising steps in the right direction, a new product, Snus, was recently cleared by the FDA to be marketed with the verbiage “instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis [4].” Could this be the second wave of the youth smoking epidemic?

DeLeon believes so. “However people want to look at SNUS—either as an alternative to smoking or as an origination to nicotine use–it’s still carcinogenic to humans. My main focus is on helping kids and young adults steer clear of nicotine. The more we paint a reduced perception of harm, the more we increase adolescent use of these products.”

The FDA wants to make a clear distinction that the modified risk claim was approved–snus are not FDA approved. But DeLeon said the distinction may get lost in the advertising copy.

“I saw the vaping epidemic happen years before it did—and snus could be the next big thing with this modified messaging. We need to educate kids now before any more deaths happen in this country from nicotine,” said DeLeon.

In addition to snus, the bans on e-cigarette flavors in various states across the country and done voluntarily to some extent by the industry leader, JUUL, will not help stem youth use. In fact, it will increase faster than ever. There are countless companies marketing and selling counterfeit flavors all over this country and online. There is a complete industry selling flavors separately which won’t fall under bans. There is a burgeoning black market that is stepping up faster than ever since the scattered bans. The worst increase of availability will come from the marijuana industry. This is a huge market that is not regulated at all by our federal government.

DeLeon delivers a hard-hitting educational program, “Vaping Me Crazy,” to youth, families, and communities across the country. Currently, Michael and his team are focusing his awareness efforts on educating parents and teachers.

“We are in the worst public social health crisis America has ever seen,” DeLeon notes. “With vaping/JUULing and a culture that literally grew up with pills marketed as the solution for every human ailment, the threat to our youth is greater than ever.”

About Michael DeLeon

Michael DeLeon has become the #1 School Presenter in America, visiting 616 schools to date in 40 states in 2018 alone. Michael is the leading subject matter expert on vaping and current youth drug trends. He is the Founder and CEO of Steered Straight, a non-profit organization providing educational programs and materials to youth, families, and communities across the country and around the world. He is a thought leader in the addiction and substance abuse community and is an advocate for social and public health change, parent/teacher education, and is spearheading multiple anti-vape campaigns and awareness programs.

# # #

1. “Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 25 Oct. 2019.

2. Aubrey, Allison. “Juul Suspends Sales of Flavored Vapes And Signs Settlement To Stop Marketing To Youth.” NPR, NPR, 17 Oct. 2019

3. Ibid.

4. Christensen, Jen. “Smokeless Tobacco Company Can Advertise Snus as Less Risky than Cigarettes, FDA Says.” CNN, Cable News Network, 22 Oct. 2019

Share article on social media or email:

Catherine Jonash, Vice President, General Manager for Virtudent’s New England Region

Working in healthcare over the last decade I’ve seen many areas where health disparities exist and one of the greatest gaps is in access to oral healthcare, said Catherine Jonash, Vice President, General Manager for Virtudent’s New England region.

BOSTON (PRWEB)
October 31, 2019

Virtudent, Inc. (http://www.virtudent.com), the leading provider of teledentistry services for employers, today announced they have appointed Catherine Jonash as Vice President, General Manager for New England. She will be responsible for overseeing all aspects of Virtudent’s operations in the region as well as increasing access to the company’s high quality, preventive dental care by bringing it to more workplaces in the New England states.

“Working in healthcare over the last decade I’ve seen many areas where health disparities exist and one of the greatest gaps is in access to oral healthcare,” said Jonash. “It’s a silent epidemic that was identified long ago, but little is being done about it. I am excited to be able to provide such a high-quality, patient-centric service that meets more people where they are today and helps to improve their overall health.”

Virtudent brings diagnostic and preventive services typically performed at a dentist’s office, including a complete oral health exam, cleaning and X-rays, to the patient’s workplace using a proprietary portable dental system. Experienced dentists and advisors from top dental schools including Boston University Dental School, Columbia Dental, Harvard School of Dental Medicine, Johns Hopkins and Tufts Dental School provide clinical oversight and review all Virtudent patient cases, assessments and X-rays. Virtudent’s experienced, degreed dental hygienists and dentists are all licensed in the state they serve and receive rigorous training in Virtudent’s proprietary solution and patient care techniques.

In New England, Virtudent operates in over 100 workplaces, including Dunkin’ Brands, Microsoft and Wayfair.

At Massachusetts Eye and Ear, for six years, Jonash oversaw 20 outpatient clinics, ensuring the best possible care and patient experience. She has also worked for Boston Healthcare Associates and California Pacific Medical Center. She earned a Master’s in Public Health from The Dartmouth Institute for Health Policy and Clinical Practice, a Master’s in Business from Dartmouth College and Bachelor’s in History from Princeton.

“Catherine’s commitment to providing the best possible experience for our New England customers is second to none and we are incredibly excited to have her on our team,” said Dave Drap, chief growth officer for Virtudent.

About Virtudent

Founded in 2014 and headquartered in Boston, Virtudent is a teledentistry practice committed to improving overall health and well-being by providing easy access to high-quality, prevention-focused dental care in the workplace. Through partnerships with hundreds of top employers, including Dunkin’ Brands, Microsoft and Wayfair, they have saved their clients tens of thousands of employee work hours. Their business model brings together experienced dentists, highly-trained hygienists and a unique portable dentistry kit in a convenient setting to address often overlooked oral health. For more information, visit http://www.virtudent.com.

Share article on social media or email: